La plateforme Quantexa a obtenu une place de choix dans le rapport RiskTech100® 2025, soulignant ainsi sa force et son innovation sur le marché en expansion de la technologie des risques et de la conformité LONDRES, 22 oct. 2024 (GLOBE NEWSWIRE) — La plateforme Quantexa, l’un des principaux fournisseurs de solutions d’intelligence décisionnelle pour les […]
Day: October 22, 2024
Exclusive Markets Receives Top Honors at International Business Magazine Awards 2024
Exclusive Markets Receives Top Honors at International Business Magazine Awards 2024 Excellence Recognized: Exclusive Markets Secures Top Award at International Business Magazine 2024 DUBAI, United Arab Emirates, Oct. 22, 2024 (GLOBE NEWSWIRE) — Exclusive Markets, a globally renowned leader in online multi-asset trading, has once again showcased its commitment to excellence by holding several prestigious […]
Exclusive Markets Honoured with “Top Trusted Financial Institution in the Financial Markets” Award in 2024
Exclusive Markets Honoured with “Top Trusted Financial Institution in the Financial Markets” Award in 2024 Exclusive Markets Shines as 2024’s Most Trusted Name in Financial Markets DUBAI, United Arab Emirates, Oct. 22, 2024 (GLOBE NEWSWIRE) — Exclusive Markets, a globally celebrated online multi-asset trading platform, has been awarded the prestigious title of Top Trusted Financial Institution […]
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of recurrent C. diff. each […]
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks catalytic activity of the toxin’s innate glucosyltransferase in order to inhibit the toxin produced by C. diff. in the gastrointestinal tract. There are up to 175,000 cases of recurrent C. diff. each […]
Incroyable Jeff ! IriusRisk présente un outil basé sur l’IA capable de générer des modèles de menaces à partir d’images
La plateforme de modélisation des menaces lance « Jeff : Assistant IA », une première mondiale en termes de création de modèles de menaces à travers le langage et les images. Cette nouvelle fonctionnalité marque l’un des tout derniers développements de la percée d’IriusRisk dans le domaine de l’IA, initiative qui a contribué à générer une croissance de […]